RecruitingPhase 2NCT06968845
Respiratory
Idiopathic Pulmonary Fibrosis
Also known as IPF, cryptogenic fibrosing alveolitis, UIP pattern
Idiopathic pulmonary fibrosis is a chronic, progressive, and ultimately fatal fibrosing interstitial lung disease of unknown cause, occurring primarily in older adults. Histologically and radiologically characterised by a usual interstitial
83
studies recruiting now
as of 7 Sept 2026
632
studies registered in total
as of 7 Sept 2026
20
countries with a recruiting site
as of 7 Sept 2026
16 Dec 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT07230288
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
RecruitingPhase 3NCT07284602
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
RecruitingPhase 2NCT07036523
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RecruitingPhase 2NCT05571059
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 83 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Idiopathic Pulmonary Fibrosis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: PFF Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is a chronic, progressive, and ultimately fatal fibrosing interstitial lung disease of unknown cause, occurring primarily in older adults. Histologically and radiologically characterised by a usual interstitial pneumonia pattern, IPF leads to progressive scarring of lung tissue, worsening dyspnoea, and declining lung function. Two antifibrotic agents, nintedanib and pirfenidone, slow progression but do not reverse the disease.
Common clinical features
Progressive dyspnoea on exertionPersistent dry coughBibasilar fine crackles on auscultationClubbing of fingers and toesFatigueHoneycombing with traction bronchiectasis on HRCTHypoxaemia and declining DLCO
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
5 approved treatments and 84 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Nintedanib (Nintedanib component of ofev)Approved: Interferon Gamma-1b (Actimmune)Approved: Pirfenidone (Esbriet)Approved: Nintedanib Esylate (Nintedanib accord)Approved: Prednisolone Sodium Phosphate (Codelsol)
Phase 3Sildenafil
Phase 3Prednisone (Cortan)
Phase 3Trimethoprim (Ipral)
Phase 3Sulfamethoxazole (Gantanol)
Phase 3Pyruvate Sodium
Phase 3Treprostinil (Remodulin)
Phase 3Bosentan (Stayveer)
Phase 3Morphine Sulfate (Arymo er)
+ 76 more in development
Before you apply
Things trial teams commonly ask about for Idiopathic Pulmonary Fibrosis. Not eligibility rules; those are set by each study.
- Most trials require a confirmed UIP pattern on HRCT or surgical lung biopsy and a minimum FVC (commonly ≥45%) and DLCO (commonly ≥30%); have recent PFTs available.
- Current use of nintedanib or pirfenidone may be a criterion or exclusion depending on the study; clarify whether the trial is add-on or treatment-naive.
- Acute exacerbations within a defined period (typically 6 months) frequently trigger exclusion; apply during a clinically stable phase.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).